Portopulmonary Hypertension

Clinics in Liver Disease

Volumn 10, Issue 3, 2006, Pages 653-663

  Passarella, Michael ^a   Fallon, Michael B ^a,b   Kawut, Steven M ^c,d  

^a and Clinical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SEROTONIN; SILDENAFIL; UNIPROST; WARFARIN;

ARTERIAL GAS; ASCITES; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; ESOPHAGUS VARICES; EXERCISE; HEART CATHETERIZATION; HEART OUTPUT; HEART PRELOAD; HEPATOPULMONARY SYNDROME; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; PULMONARY ARTERY CATHETER; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY, DOPPLER; EPOPROSTENOL; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS;

EID: 33845293378     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.023     Document Type: Review

References (73)

1. Simonneau G., Galie N., Rubin L., et al. Clinical classification of pulmonary hypertension. J Am Coll Cariol 43 (2004) 5S-12S
2. Budhiraja R., and Hassoun P.M. Portopulmonary hypertension: a tale of two circulations. Chest 123 (2003) 562-576
3. Rodriquez-Roisin R., Krowka M.J., Herve P., et al. Pulmonary-hepatic vascular disorders. Eur Respir J 24 (2004) 861-880
4. Krowka M.J. Portopulmonary hypertension: diagnostic advances and caveats. Liver Transpl 9 (2003) 1336-1337
5. Groves B.M., Brundage B.H., Elliot C.G., et al. Pulmonary hypertension associated with hepatic cirrhosis. In: Fishman A.P. (Ed). The pulmonary circulation: normal and abnormal (1990), University of Pennsylvania Press, Philadelphia 359-369
6. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
7. Mandell M.S., and Groves B.M. Pulmonary hypertension in chronic liver disease. Clin Chest Med 17 (1996) 17-33
8. Krowka M.J., Mandell S., Ramsay M.A., et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 10 (2004) 174-182
9. Edwards B.S., Weir E.K., Edwards M.D., et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 10 (1987) 1233-1238
10. Schraufnagel D.E., and Kay J.M. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 17 (1996) 1-15
11. Naeye R.L. Primary pulmonary hypertension and coexisting portal hypertension. A retrospective study of six cases. Circulation 22 (1960) 376-384
12. Lee S.D., Shroyer K.R., Markham N.E., et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101 (1998) 927-934
13. Kuo P.C., Plotkin J.S., Gaine S., et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 67 (1999) 1087-1093
14. Ruttner J.R., Bartschi J.P., Niedermann R., et al. Plexogenic arteriopathy and liver cirrhosis. Thorax 35 (1980) 133-136
15. Pietra G.G. Histopathology of primary pulmonary hypertension. Chest 105 (1994) 2S-6S
16. Cool C.D., Stewart J.S., Werahera P., et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155 (1999) 411-419
17. Yaginuma G., Mohri H., and Takahashi T. Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: a computer aided reconstruction study. Thorax 45 (1990) 586-590
18. Ogata T., and Lijima T. Structure and pathogenesis of plexiform lesion in pulmonary hypertension. Chin Med J (Engl) 106 (1993) 45-48
19. Krowka M.J., and Edwards W.D. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transpl 6 (2000) 2421-2422
20. Wagenvort C.A., and Mulder P.G. Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?. Chest 103 (1993) 844-849
21. Christman B.W., Mcpherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
22. Maruyama T., Ohsaki K., Shimoda S., et al. Thromboxane-dependent portopulmonary hypertension. Am J Med 118 (2005) 93-94
23. Benjaminov F.S., Prentice M., Sniderman K.W., et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52 (2003) 1355-1362
24. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108 (2001) 1141-1150
25. Herve P., Launay J.M., Scrobohaci M.L., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99 (1995) 249-254
26. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26 (2000) 81-84
27. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
28. McDonnell P., Toye P., and Hutchins G. Primary pulmonary hypertension and cirrhosis: are they related?. Am Rev Respir Dis 127 (1983) 437-441
29. Hadengue A., Benhayoun M.K., Lebrec D., et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 100 (1991) 520-528
30. Yang Y.Y., Lin H.C., Lee W.C., et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 36 (2001) 181-186
31. Castro M., Krowka M.J., Schroeder D.R., et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 71 (1996) 543-551
32. Torregossa M., Genesca J., Gonzalez A., et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 71 (2001) 572-574
33. Ramsay M.A., Simpson B., Nguyen A.T., et al. Severe pulmonary hypertension in liver transplantation candidates. Liver Transpl Surg 3 (1997) 494-500
34. Taura P., Garcia-Valdecasas J.C., Beltran J., et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 83 (1996) 675-680
35. Plevak D., Krowka M.J., Rettke S., et al. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. [letter]. Transplant Proc 25 (1993) 1840
36. Colle I.O., Moreau R., Godinho E., et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology 37 (2003) 401-409
37. Donovan C.L., Marcovitz P.A., Punch J.D., et al. Two-dimensional, and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 61 (1996) 1180-1188
38. Swanson K.L., McGoon M.D., and Krowka M.J. Survival in portopulmonary hypertension. [abstract]. Am J Respir Crit Care Med 167 (2003) A683
39. Herve P., Lebrec D., Brenot F., et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 11 (1998) 1153-1166
40. Kawut S.M., Taichman D.B., Ahya V.N., et al. Hemodyanamics and survival of patients with portopulmonary hypertension. Liver Transpl 11 (2005) 1107-1111
41. Krowka M.J. Pulmonary hypertension. Mayo Clin Proc 75 (2000) 625-630
42. Gaine S. Pulmonary hypertension. JAMA 284 (2000) 3160-3168
43. Molden D., and Abraham J.L. Pulmonary hypertension: its association with hepatic cirrhosis and iron accumulation. Arch Pathol Lab Med 106 (1982) 328-331
44. Krowka M.J. Hepatapulmonary syndrome vs. portopulmonary hypertension: distinctions and dilemmas. Hepatology 25 (1997) 1282-1284
45. Kuo P.C., Plotkin J.S., Johnson L.B., et al. Distinctive clinical features of portopulmonary hypertension. Chest 112 (1997) 980-986
46. Swanson K., and Krowka M. Arterial oxygenation associated with portopulmonary hypertension. Chest 121 (2002) 1869-1875
47. Chan T., Palevsky H.I., and Miller W.T. Pulmonary hypertension complicating portal hypertension: findings on chest radiographs. AJR Am J Roentgenol 151 (1988) 909-914
48. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 201-211
49. Kim W.R., Krowka M.J., Plevak D.J., et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 6 (2000) 453-458
50. Ota K., Shilo H., Kokawa H., et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 10 (1995) 198-204
51. Navasa M., Bosch J., Reichen J., et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 8 (1988) 850-854
52. Provencher S., Herve P., Jais X., et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130 (2006) 120-126
53. Rubin L., Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
54. Makisalo H., Koivusalo A., Vakkuri A., et al. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Translp 10 (2004) 945-950
55. Halank M., Miehlke S., Hoeffken G., et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 77 (2004) 1775-1776
56. Hinterhuber L., Graziadei I.W., Kahler C.M., et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2 (2004) 1039-1042
57. Kuntzen C., Gulberg V., and Gerbes A.L. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?. Gastroenterology 128 (2005) 164-168
58. Hoeper M.M., Halank M., Marx C., et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 25 (2005) 502-508
59. Halank M., Kolditz M., Miehlke S., et al. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. Wein Med Wochenschr 155 (2005) 376-380
60. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
61. Chua R., Keogh A., and Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 24 (2005) 498-500
62. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
63. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
64. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
65. Kuo P.C., Johnson L.B., Plotkin J.S., et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63 (1997) 604-606
66. Krowka M.J., Frantz R.P., McGoon M.D., et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30 (1999) 641-648
67. Findlay J.Y., Plevak D.J., Krowka M.J., et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 5 (1999) 362-365
68. Halank M., Marx C., Miehlke S., et al. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 39 (2004) 1222-1223
69. Krowka M., Plevak D., Findlay J., et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6 (2000) 443-450
70. Kawut S., Horn E., Berekashvili K., et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 95 (2005) 199-203
71. Mclaughlin V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
72. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
73. Starkel P., Vera A., Gunson B., et al. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 8 (2002) 382-388